Stock Events

Intellia Therapeutics 

$27.42
196
+$0.54+2.01% Today

Statistics

Day High
27.57
Day Low
-
52W High
47.48
52W Low
22.67
Volume
1,102,334
Avg. Volume
1,672,791
Mkt Cap
2.46B
P/E Ratio
-5.13
Dividend Yield
-
Dividend
-

Earnings

22FebConfirmed
Q2 2022
Q3 2022
Q4 2022
Q1 2023
Q2 2023
Q3 2023
Q4 2023
-1.5
-1.39
-1.28
-1.17
Expected EPS
-1.45
Actual EPS
-1.46

People Also Follow

This list is based on the watchlists of people on Stock Events who follow NTLA. It's not an investment recommendation.

Analyst Ratings

77.86$Average Price Target
The highest estimate is $136.
From 8 ratings within the last 6 months. This is not an investment recommendation.
Buy
88%
Hold
13%
Sell
0%

About

Health Technology
Biotechnology
Manufacturing
Pharmaceutical Preparation Manufacturing
Intellia Therapeutics, Inc., a genome editing company, focuses on the development of therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; and NTLA-2002 for the treatment of hereditary angioedema, as well as other liver-focused programs comprising hemophilia A and hemophilia B, hyperoxaluria Type 1, and alpha-1 antitrypsin deficiency. Its ex vivo pipeline includes NTLA-5001 for the treatment of acute myeloid leukemia; and proprietary programs focused on developing engineered cell therapies to treat various oncological and autoimmune disorders. In addition, it offers tools comprising of Clustered, Regularly Interspaced Short Palindromic Repeats/CRISPR associated 9 (CRISPR/Cas9) system. Intellia Therapeutics, Inc. has license and collaboration agreements with Novartis Institutes for BioMedical Research, Inc. to engineer hematopoietic stem cells for the treatment of sickle cell disease; Regeneron Pharmaceuticals, Inc. to co-develop potential products for the treatment of hemophilia A and hemophilia B; Ospedale San Raffaele; and a strategic collaboration with SparingVision SAS to develop novel genomic medicines utilizing CRISPR/Cas9 technology for the treatment of ocular diseases. The company was formerly known as AZRN, Inc. Intellia Therapeutics, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.
Show more...
CEO
John Leonard
Employees
485
Country
US
ISIN
US45826J1051
WKN
000A2AG6H

Listings